














Oral anBuffered Versus Non-Buffered
Lidocaine With Epinephrine for
Mandibular Nerve Block: Clinical
Outcomes
James A. Phero, DDS, MD,* Blake Nelson, BS, DDS,y Bobby Davis, BS,z
Natalie Dunlop, BS,x Ceib Phillips, PhD, MPH,k Glenn Reside, DDS,{
Andrew P. Tikunov, PhD,# and Raymond P. White, Jr, DDS, PhD**Purpose: Outcomes for peak blood levels were assessed for buffered 2% lidocaine with 1:100,000
epinephrine compared with non-buffered 2% lidocaine with 1:100,000 epinephrine.
Patients and Methods: In this institutional review board–approved prospective, randomized, double-
blinded, crossover trial, the clinical impactof buffered2% lidocainewith1:100,000epinephrine (AnutraMed-
ical, Research Triangle Park, Cary, NC) was comparedwith the non-buffered drug. Venous blood samples for
lidocainewere obtained 30minutes after amandibular nerve blockwith 80mgof the buffered or unbuffered
drug. Twoweeks later, the same subjects were tested with the alternate drug combinations. Subjects also re-
portedonpainon injectionwith a 10-point Likert-type scale and time to lower lip numbness. The explanatory
variable was the drug formulation. Outcome variables were subjects’ peak blood lidocaine levels, subjective
responses to pain on injection, and time to lower lip numbness. Serum lidocaine levels were analyzed with
liquid chromatography-mass spectrometry. Statistical analyses were performed using Proc TTEST (SAS 9.3;
SAS Institute, Cary, NC), with the crossover option for a 2-period crossover design, to analyze the normally
distributed outcome for pain. For non-normally distributed outcomes of blood lidocaine levels and time to
lower lip numbness, an assessment of treatment difference was performed using Wilcoxon rank-sum tests
with Proc NPAR1WAY (SAS 9.3). Statistical significance was set at a P value less than .05 for all outcomes.
Results: Forty-eight percent of subjects were women, half were Caucasian, 22% were African American,
and 13% were Asian. Median age was 21 years (interquartile range [IQR], 20-22 yr), and median body
weight was 147 lb (IQR, 130-170 lb). Median blood levels (44 blood samples) at 30 minutes were
1.19 mg/L per kilogram of body weight. Mean blood level differences of lidocaine for each patient were
significantly lower after nerve block with the buffered drug compared with the non-buffered agent (P <
.01). Mean score for pain on injection for nerve block (n = 46 scores) was 3.3 (standard deviation, 0.9).
Seventy-eight percent of subjects reported lower or the same pain scores with the buffered drug; 61%
of subjects reported a shorter time to lower lip numbness with the buffered drug.ed from the School of Dentistry, University of North Carolina,
l Hill, NC.
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J Oral Maxillofac Surg 75:688-693, 2017Local anesthetics have been a key component of
dental treatment since the beginning of the 20th cen-
tury. Based on the discovery of the anesthetic effects
of the drug and the invention of the hypodermic sy-
ringe at the end of the 19th century, cocaine was
rapidly adopted as a means of blocking painful sensory
impulses during surgical procedures.1 The discovery
of procaine early in the 20th century led to this newer
drug replacing cocaine to avoid its potential addictive
properties. Lidocaine and its derivative products of the
late 20th century, mepivacaine, bupivacaine, and arti-
caine, are widely used to control pain with invasive
oral procedures.2 Local anesthetics are being adminis-
tered in anesthesiology for pain control during and af-
ter orthopedic and head and neck procedures. In
addition, for postprocedure pain control, longer-
acting local anesthetics have been administered to pro-
duce long-term sensory nerve blockade, thus
decreasing the need for analgesic drugs after proced-
ures, particularly opioids.3
The addition of a vasopressor, usually epinephrine,
to lidocaine and other injected local anesthetics serves
to prolong the anesthetic effect by decreasing blood
flow to the anatomic area and the diffusion of the
drug away from the anatomic site of injection. To pro-
long the shelf life of the vasopressor, the drug combi-
nation must be formulated with a low pH (3.5) for
lidocaine with epinephrine. When lidocaine with
epinephrine is injected, the combination of the needle
penetration of tissue and the low pH of the solution
causes an unpleasant or painful sensation often re-
ported by subjects. Buffering the drug to a neutral
pH could make the injection more comfortable for
the patient.
By current consensus of clinicians and biological sci-
entists, to be effective, a local anesthetic drug must
penetrate the nerve membrane blocking the voltage-
gated sodium channel preventing depolarization.4
No longer is this considered an action only at the sur-
face of the targeted nerve. Because only the unionized
form of the drug penetrates the affected nerve mem-
brane, a local anesthetic drug should be more effective
in onset and potency if the pH is closer to the drugs’
acidity constant (pKa) when more of the drug is in
the unionized form. For lidocaine, the pKa is approxi-
mately 8.0, with minor variation dependent on tem-
perature.5 The drug injected at a neutral pH
decreases the need and time lag for buffering by tissue
fluid and makes the maximum unionized form of the
drug immediately available while retaining the desiredqualities of the vasopressor.6 Until recently, buffering
the drug combination with bicarbonate just before
injection was impractical for many of themore compli-
cated, protracted procedures in dentistry. However, a
kit capable of efficiently buffering an adequate volume
of lidocaine with epinephrine for any procedure
immediately before injection became available in
2015 (Anutra Medical, Research Triangle Park,
Cary, NC).
Investigators have reported less pain on injection of
buffered lidocaine with epinephrine into skin when
the pH of the drug is closer to 7.4.7-9 Previous
clinical studies in dentistry, not all from peer-
reviewed journals, have reported similar but not
universally consistent results.10-13 Subjects injected
intraorally for mandibular nerve block with buffered
lidocaine tended to have a faster onset of lower lip
numbness, with differences no greater than
5 minutes, and less pain on injection, but not always.
Mean maximum blood levels of local anesthetic
occur approximately 30 minutes after oral injection.14
Buffering local anesthetics might alter peak blood lido-
caine levels compared with the non-buffered drug.
Blood lidocaine levels could be similar, lower, or
higher. However, no data have been published on
peak blood levels for buffered lidocaine anesthetics
used in dental and oral surgical procedures.
This study, with a crossover design with each
patient also serving as a control, was planned to deter-
mine relative blood levels of buffered lidocaine after
oral injection for mandibular nerve block compared
with the unbuffered combination. This useful informa-
tion to clinicians on the metabolism and potential sys-
temic toxicity of lidocaine could be important for
subjects with dosage limitations because of body
weight or health issues. In addition, the study was de-
signed to substantiate previous reports of less pain on
injection and earlier onset of anesthesia with the buff-
ered drug.Patients and Methods
Twenty-four subjects were recruitedwith a protocol
approved by the institutional review board of the Uni-
versity of North Carolina (UNC; Chapel Hill, NC), and
treated in 2 sessions at the UNC Oral and Maxillofacial
Surgery Clinic; 23 subjects completed the 2 study ses-
sions. According to the protocol, subjects served as
their own controls in a crossover study design. The
sample size in this pilot study was chosen to provide
Table 1. DEMOGRAPHIC CHARACTERISTICS OF
SUBJECTS, SERVING AS THEIR OWN CONTROLS,
RANDOMLY RECEIVING BUFFERED AND
NON-BUFFERED 2% LIDOCAINE WITH 1:100,000
EPINEPHRINE (N = 23)
Men, n (%) 12 (52)
Women, n (%) 11 (48)
Weight (lb), median (IQR) 147 (130-170)
Age (yr), median (IQR) 21 (20-22)
Ethnicity or race, n (%)
Caucasian 12 (52)
African American 5 (22)
Asian 3 (13)
Other 3 (13)
Abbreviation: IQR, interquartile range.
Phero et al. Buffered Lidocaine for Mandibular Nerve Block. J Oral
Maxillofac Surg 2017.
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that would be required in larger studies with a more
diverse population.
A block randomization was used to randomize
subjects to sequence 1: 4 mL of non-buffered 2% lido-
caine (80 mg) with 1:100,000 epinephrine given in
period 1 and 4 mL of buffered 2% lidocaine (80 mg)
with 1:100,000 epinephrine given in period 2; or to
sequence 2: 4 mL of buffered 2% lidocaine (80 mg)
with 1:100,000 epinephrine given in period 1 and
4 mL of non-buffered 2% lidocaine (80 mg) with
1:100,000 epinephrine given in period 2. The buffered
local anesthetics were adjusted to a neutral pH with
bicarbonate just before injection for nerve block (Anu-
tra Medical). The syringe for the buffered drug in each
period had an added volume of 8.4% sodium bicarbon-
ate 0.4 mL to compensate for the bicarbonate added to
the lidocaine. The same investigator loaded the
syringes with the local anesthetic drugs for the 2 clin-
ical study sessions.
A midlevel oral and maxillofacial surgical resident
and a full-time faculty member shared the task of
administering the mandibular nerve block. The clini-
cians and the subjects were masked to the drug admin-
istered at each clinical session.
In week 1, each patient received an anesthetic to
block the inferior alveolar and lingual nerves with
the Halstead techniques. No buccal nerve block was
administered to avoid the chance of pain from stimula-
tion of the periosteum covering the coronoid process.
At least 1 week later, sufficient to exceed the washout
period for the drug, the nerve block involved the alter-
nate local anesthetic combination.
Venous blood samples were drawn from the antecu-
bital fossa 30 minutes after the injection of the local
anesthetic at each of the 2 clinical sessions and assayed
for serum lidocaine levels with a Sciex TripleTOF
liquid chromatography-mass spectrometry (LC-MS;
Sciex, Framingham, MA) equipped with a C18 Hyper-
sil (10  2.1 mm, 3.0 mm) using methods previously
described by Dal Bo et al.15
At each visit, assessment for pain level on injection
was reported by each patient to a clinical investigator
based on a 10-point Likert-type scale anchored by no
pain and worst pain imaginable. A timed assessment
was performed after the anesthetic for clinical onset
of anesthesia by the patient reporting to the same clin-
ical investigator when the lower lip was numb on the
injected side.
The explanatory variable was the drug formulation.
Outcome variables were the LC-MC–assessed values
for blood lidocaine levels, subjects’ subjective re-
sponses to pain on injection, and time to lower lip
numbness. Statistical analyses were performed using
Proc TTEST (SAS 9.3; SAS Institute, Cary, NC), with
the crossover option for a 2-period crossover design,to analyze the normally distributed continuous
outcome for pain. For non-normally distributed contin-
uous outcomes for blood lidocaine levels and time to
lower lip numbness, an assessment of treatment differ-
ence was performed using Wilcoxon rank-sum tests
with Proc NPAR1WAY (SAS 9.3).16 Statistical signifi-
cance was set at a P value less than .05 for
all outcomes.Results
Forty-eight percent of the 23 subjects completing
the protocol were women, half were Caucasian, 22%
were African American, and 13% were Asian
(Table 1). Median age was 21 years (interquartile range
[IQR], 20-22 yr) and median body weight was 147 lb
(IQR, 130-170 lb).
The median blood lidocaine level at 30 minutes after
injection for 22 subjects (44 blood samples) was
70 mg/L (IQR, 62-87 mg/L). Compared by body weight,
the median blood level of lidocaine at 30 minutes for
all subjects was 1.19 mg/L per kilogram of bodyweight.
Median blood lidocaine levels were significantly
higher (15 mg/L) for the injected non-buffered lido-
caine than for the buffered lidocaine (95% confidence
interval [CI], 5.8-34.6; P = .006; Fig 1). Conversely, the
outcomes suggested that blood lidocaine values were
markedly lower when the injected drug was buffered.
When subjects received non-buffered lidocaine, 16 of
22 subjects (73%) had a blood lidocaine concentration
that was higher than with the buffered lidocaine, 3
(13%) had the same level calculated as less or equal
to 1.6 mg/L, and 3 (13%) had a blood lidocaine concen-
tration that was lower.
Based on all responses on the 10-point Likert scale,
the mean score for pain on injection for nerve block
FIGURE 1. Subjects’ (n = 22) peak venous blood levels of lido-
caine in samples taken 30 minutes after injection comparing differ-
ences for the same patient between buffered 2% lidocaine with
1:100,000 epinephrine and non-buffered 2% lidocaine with
1:100,000 epinephrine.
Phero et al. Buffered Lidocaine for Mandibular Nerve Block. J Oral
Maxillofac Surg 2017.
FIGURE 2. Subjects’ (N = 23) reporting time to a numb lower lip
after injection comparing differences for the same patient between
buffered 2% lidocaine with 1:100,000 epinephrine and non-
buffered 2% lidocaine with 1:100,000 epinephrine.
Phero et al. Buffered Lidocaine for Mandibular Nerve Block. J Oral
Maxillofac Surg 2017.
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Although not statistically significant, on average,
slightly lower scores, approximately two thirds of 1
U (95% CI, 1.46 to 0.13), were reported with the
buffered lidocaine (P = .096). Of 23 subjects, 17
(78%) reported the same or lower pain scores with
the buffered drug combination compared with the
non-buffered lidocaine.
Median time to lower lip numbness after nerve
block (n = 46 scores) was 3 minutes (IQR, 2-4 mi-
nutes). The difference in time between the 2 drug for-
mulations was not statistically significant (P = .23).
Subjects’ median time to lip numbness for the buffered
lidocaine compared with the non-buffered drug
was 1 minute (IQR, 4 to +1; 95% CI, 18 to 6.6;
Fig 2). Time to lip numbness with the buffered lido-
caine was shorter for 14 subjects (61%). For 8 subjects
(35%), time to lip numbness was shorter for the non-
buffered lidocaine.Discussion
The present data on peak lidocaine blood levels
markedly favor outcomes after the buffered lidocaine
with epinephrine; blood levels at 30 minutes after
injection for three fourths of subjects were lower
for the buffered lidocaine. These comparative data
on blood lidocaine levels with buffered and non-
buffered lidocaine with epinephrine have not previ-
ously been reported in the literature. This suggests
to clinicians that the buffered lidocaine does not in-
crease systemic toxicity after injection of the buffered
lidocaine with epinephrine compared with the same
dosages of the unbuffered drug. The lidocaine dosage
in this study (80 mg) is often administered to
adequately perform a procedure in 1 quadrant of themandible requiring pulpal and periosteal anesthesia.
For subjects in this study whose weight averaged
147 lb (67 kg), the dosage of 80mg iswell below a con-
servative suggested maximum dosage of lidocaine
(5 mg/kg or 335 mg). If results with the buffered
drug had been marginally higher compared with the
non-buffered drug, then it likely would not have posed
a clinical problem with most dental procedures.
However, for subjects with much lower body weight
or those with compromised liver function, a higher
blood lidocaine level even with low dosages might
be problematic. If these data suggesting lower peak
venous blood levels of lidocaine with the buffered
lidocaine with epinephrine can be substantiated
with larger volumes of the drug in future clinical trials,
choosing the buffered drug combination might be
preferred for pediatric and other select subjects,
particularly those with compromised liver function.
The outcome of this study, less pain on injections
into skin with buffered lidocaine, has been reported
consistently. In 25 adult volunteers, less pain was re-
ported after intradermal 0.5-mL injections of the buff-
ered drug compared with the non-buffered drug.7
Masters8 reported similar results with the buffered
local anesthetic administered in skin for plastic sur-
gery procedures. Of the 40 subjects in that study,
half the procedures were performed on the face. Simi-
larly, Lee et al9 reported less pain with buffered lido-
caine than with non-buffered lidocaine in hand
surgery, a traditionally painful anatomic site for injec-
tions. These results were noted after a topical anes-
thetic cream was applied to the skin according to
the protocol to minimize the impact of needle punc-
ture in the 2 groups of subjects.
The present data on pain with injection for nerve
block mirror outcomes from previous clinical studies
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contrast to injections of the skin, a field block for local
anesthesia, the data for pain from intraoral injections
for nerve block are not uniformly predictable.10-13
Although not always statistically relevant, subjects
injected intraorally for mandibular nerve block
generally have less or the same pain on injection
with buffered lidocaine, but not always. Other
factors than the pH of the drug formulation are
involved, including needle penetration of the
mucosa, the volume and speed of the solution
injected, the variable potential of penetration of the
periosteum during injection, and the anatomic
proximity of the injected drug to the targeted nerve
trunk. These differences compared with a field block
for anesthesia in the skin could explain the
different outcomes.
Although not consistent across all subjects in the
study, a faster onset of lower lip numbness was re-
ported by two thirds of subjects when lidocaine with
epinephrine was buffered just before administration.
Kashyap et al11 and Malamed et al12,13 suggested an
earlier onset of anesthesia for most, but not all,
subjects with buffered lidocaine with 1:100,000
epinephrine compared with non-buffered drugs. The
rationale for an earlier onset of anesthesia, usually a dif-
ference in minutes, for buffered preparations of local
anesthetic drugs with epinephrine compared with
non-buffered drugs is based on the time lag after injec-
tion for tissue fluids to buffer the lower pH levels of 3.5
of commercial preparations to 7.4. After buffering lido-
caine with epinephrine with bicarbonate, the com-
mercial preparation has a pH closer to the drug’s
pKa (for lidocaine, the pKa is 8.0), making more of
the unionized form of the drug more rapidly available
to the targeted nerve trunk, resulting in a faster onset
of anesthesia.
Clinicians should consider that the present data
have limitations. Administered drug dosages were
low and not close to maximum recommended dosages
by body weight. Thus, peak blood levels were low
overall. Although blood lidocaine levels usually are re-
ported at 30 minutes after injection, the beneficial out-
comes reported for the buffered lidocaine could differ
if peak blood levels occur within less than 30 minutes.
Although the experimental design uniquely compared
outcomes for the same patient 2 weeks apart and nu-
merical values were assigned to the outcomes for
pain on injection and onset of lip numbness, the
data were subjective, relying on the subjects’ interpre-
tation and responses. All subjects studied were young
healthy adults. Potential patients with a more compro-
mised health status or different dental experiences
might report other responses. Although it was clear
that the drug buffered just before injection was associ-
ated with less or the same pain for most subjects oninjection of the local anesthetic for nerve block, a clear
benefit, pain levels on a 10-point Likert-type scale over-
all were low (average, 3 of 10). Although the buffered
lidocaine did result in many of the subjects having a
numb lip more rapidly than occurred with the non-
buffered drug, an indication of a more rapid impact
on the targeted sensory nerves, the differences gener-
ally were only a few minutes. This benefit must be
weighed by the practice of the respective clinicians.
For example, general dentists might gain by a rapid
onset of the drug, whereas surgeons planning a more
protracted procedure might not see the same
advantages.
The present data suggest that lidocaine with
epinephrine buffered just before injection for nerve
block for mandibular procedures has positive bene-
fits for patients. Similar studies should be conducted
for outcomes after field block in the upper jaw, which
might be different. Based on current concepts of the
pharmacology of the effect of local anesthetics on tar-
geted nerves, buffering commercial preparations of
local anesthetics with epinephrine, making the
unionized form of the injected drug more rapidly
available to the targeted nerves, could allow clini-
cians to use a lower concentration by volume of the
local anesthetic. For example, buffered 1% lidocaine
with epinephrine could be as effective as non-
buffered 2% lidocaine with epinephrine. This poten-
tial should be studied for nerve block in the mandible
and field block in the maxilla, with possible outcomes
having obvious clinical benefits, particularly to pedi-
atric patients who have lower weight-determined
dosage limits. The recently available buffering kit
for this study has practical benefits for clinicians; vol-
umes of the administered buffered drug can be as
large as the capacity of the syringe chosen by the clini-
cian. In addition, studies should be conducted with a
wide range of patients with different health statuses
who might require a variety of dental and oral
procedures.
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